Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 532-543

  von Kleist, Max ^a,b   Huisinga, Wilhelm ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

CD4, Pharmacodynamics; HIV; Intra cellular phosphorylation; PBMC; Reverse transcription

Indexed keywords

RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE TRIPHOSPHATE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER MODEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG PENETRATION; ENZYME ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTITION COEFFICIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHOSPHORYLATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; STEADY STATE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS SUPPRESSION; VOLUNTEER;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 59449088562     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.12.010     Document Type: Article

References (76)

1. Acosta E.P., Page L.M., and Fletcher C.V. Clinical pharmacokinetics of zidovudine. An update. Clin. Pharmacokinet. 30 (1996) 251-262
2. Anderson P.L., Kakuda T.N., Kawle S., and Fletcher C.V. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17 (2003) 2159-2168
3. Anderson P.L., Zheng J.-H., King T., Bushman L.R., Predhomme J., Meditz A., Gerber J., and Fletcher C.V. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS 21 (2007) 1849-1854
4. ′-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J. Biol. Chem. 267 (1992) 10968-10975
5. ′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. J. Virol. 70 (1996) 712-720
6. Aweeka, F.T., Kang, M., Yu, J.-Y., Lizak, P., Alston, B., Chung, R.T., 5092s Study Team, A.I. D.S.C.T.G., 2007. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: Actg 5092s study team. HIV Med. 8, 288-294.
7. Barry M.G., Khoo S.H., Veal G.J., Hoggard P.G., Gibbons S.E., Wilkins E.G., Williams O., Breckenridge A.M., and Back D.J. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10 (1996) 1361-1367
8. Becher F., Pruvost A., Goujard C., Guerreiro C., Delfraissy J.-F., Grassi J., and Benech H. Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16 (2002) 555-565
9. Becher F., Schlemmer D., Pruvost A., Nevers M.-C., Goujard C., Jorajuria S., Guerreiro C., Brossette T., Lebeau L., Crminon C., Grassi J., and Benech H. Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells. Anal. Chem. 74 (2002) 4220-4227
10. Beerenwinkel N., Eriksson N., and Sturmfels B. Evolution on distributive lattices. J. Theor. Biol. 242 (2006) 409-420
11. +-activated potassium channel KCNN4. J. Biol. Chem. 279 (2004) 47681-47687
12. Bisset L.R., Lung T.L., Kaelin M., Ludwig E., and Dubs R.W. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur. J. Haematol. 72 (2004) 203-212
13. Blankson J.N., Persaud D., and Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53 (2002) 557-593
14. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75 (2001) 4832-4842
15. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health. 13 (1997) 407-484
16. Capparelli E.V., Englund J.A., Connor J.D., Spector S.A., McKinney R.E., Palumbo P., and Baker C.J. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J. Clin. Pharmacol. 43 (2003) 133-140
17. Cases-Gonz lez C.E., and Menndez-Arias L. Nucleotide specificity of HIV-1 reverse transcriptases with amino acid substitutions affecting Ala-114. Biochem. J. 387 (2005) 221-229
18. ′-deoxythymidine and its anabolites in control and retrovirus-infected mice. Drug Metab. Dispos. 25 (1997) 412-422
19. Clavel F., and Hance A.J. HIV drug resistance. N. Engl. J. Med. 350 (2004) 1023-1035
20. Compain S., Durand-Gasselin L., Grassi J., and Benech H. Improved method to quantify intracellular zidovudine mono- and triphosphate in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. J. Mass. Spectrom. 42 (2007) 389-404
21. Dixit N.M., Markowitz M., Ho D.D., and Perelson A.S. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir. Ther. 9 (2004) 237-246
22. Dixit N.M., and Perelson A.S. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J. Theor. Biol. 226 (2004) 95-109
23. Eilers, M., Roy, U., Mondal, D., 2008. Mrp (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp. Biol. Med. (Maywood).
24. Fletcher C.V., Kawle S.P., Kakuda T.N., Anderson P.L., Weller D., Bushman L.R., Brundage R.C., and Remmel R.P. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 14 (2000) 2137-2144
25. Flynn, P.M., Rodman, J., Lindsey, J.C., Robbins, B., Capparelli, E., Knapp, K.M., Rodriguez, J.F., McNamara, J., Serchuck, L., Heckman, B., Martinez, J., the PACTG P1012 Team, 2007. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob. Agents Chemother. 51, 3516-3522.
26. ′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol. Pharmacol. 37 (1990) 665-670
27. ′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8333-8337
28. Gail Skowron, M., Ogden, R. (Eds.), 2006. Reverse Transcriptase Inhibitors in HIV/AIDS Therapy. Humana Press, Totowa, New Jersey.
29. Gao W.Y., Johns D.G., Tanaka M., and Mitsuya H. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine. Mol. Pharmacol. 55 (1999) 535-540
30. Gitterman S.R., Drusano G.L., Egorin M.J., and Standiford H.C. Population pharmacokinetics of zidovudine. The veterans administration cooperative studies group. Clin. Pharmacol. Ther. 48 (1990) 161-167
31. Hayashi K., Pu H., Andras I.E., Eum S.Y., Yamauchi A., Hennig B., and Toborek M. HIV-tat protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J. Cereb. Blood Flow Metab. 26 (2006) 1052-1065
32. Huang Y., Rosenkranz S.L., and Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math. Biosci. 184 (2003) 165-186
33. Janneh O., Jones E., Chandler B., Owen A., and Khoo S.H. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother. 60 (2007) 987-993
34. Janneh O., Owen A., Chandler B., Hartkoorn R.C., Anthony Hart C., Bray P.G., Ward S.A., Back D.J., and Khoo S.H. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19 (2005) 2097-2102
35. Kepler T.B., and Perelson A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11514-11519
36. Koenig S., Gendelman H.E., Orenstein J.M., Canto M.C.D., Pezeshkpour G.H., Yungbluth M., Janotta F., Aksamit A., Martin M.A., and Fauci A.S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233 (1986) 1089-1093
37. Langtry H.D., and Campoli-Richards D.M. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37 (1989) 408-450
38. Lavie A., Schlichting I., Vetter I.R., Konrad M., Reinstein J., and Goody R.S. The bottleneck in AZT activation. Nat. Med. 3 (1997) 922-924
39. Luzier A., and Morse G.D. Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res. 21 (1993) 267-280
40. ′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity. Biochem. Pharmacol. 71 (2006) 1342-1348
41. Marier J.F., Dimarco M., Guilbaud R., Dodard C., Morelli G., Tippabhotla S.K., Singla A.K., Thudi N.R., and Monif T. Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. J. Clin. Pharmacol. 47 (2007) 1381-1389
42. McElrath M.J., Pruett J.E., and Cohn Z.A. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 675-679
43. Meltzer M.S., Nakamura M., Hansen B.D., Turpin J.A., Kalter D.C., and Gendelman H.E. Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Res. Hum. Retroviruses 6 (1990) 967-971
44. Mirochnick M., Rodman J.H., Robbins B.L., Fridland A., Ganda J., Hitti J., Bardeguez A., Rathore M.H., Garcia A.G., Cababasay M., Samson P., Mofenson L., Bryson Y.J., and Dorenbaum A. Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. HIV Med. 8 (2007) 451-456
45. Owen A., and Khoo S.H. Intracellular pharmacokinetics of antiretroviral agents. J. HIV Ther. 9 (2004) 97-101
46. Painter G.R., Almond M.R., Mao S., and Liotta D.C. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. Curr. Top. Med. Chem. 4 (2004) 1035-1044
47. Panhard, X., Legrand, M., Taburet, A.-M., Diquet, B., Goujard, C., Mentré, F., the Cophar 1 ANRS 102 Study Group, 2007. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur. J. Clin. Pharmacol. 63(11) 1019-1029
48. Perelson A.S. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 41 (1999) 3-44
49. Peter K., and Gambertoglio J.G. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection. Pharm. Res. 15 (1998) 819-825
50. Pierson T., McArthur J., and Siliciano R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18 (2000) 665-708
51. Piliero P.J. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 37 Suppl. 1 (2004) S2-S12
52. Rao C.V., and Arkin A.P. Stochastic chemical kinetics and the quasi-steady-state assumption: Application to the Gillespie algorithm. J. Chem. Phys. 118 (2003) 4999-5010
53. Rappersberger K., Gartner S., Schenk P., Stingl G., Groh V., Tschachler E., Mann D.L., Wolff K., Konrad K., and Popovic M. Langerhans' cells are an actual site of HIV-1 replication. Intervirology 29 (1988) 185-194
54. Ray A.S., Murakami E., Basavapathruni A., Vaccaro J.A., Ulrich D., Chu C.K., Schinazi R.F., and Anderson K.S. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 42 (2003) 8831-8841
55. Richman D.D. HIV chemotherapy. Nature 410 (2001) 995-1001
56. Rodman J.H., Robbins B., Flynn P.M., and Fridland A. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. J. Infect. Dis. 174 (1996) 490-499
57. Rosario M.C., Jacqmin P., Dorr P., van der Ryst E., and Hitchcock C. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin. Pharmacol. Ther. 78 (2005) 508-519
58. Ruane P.J., Richmond G.J., DeJesus E., Hill-Zabala C.E., Danehower S.C., Liao Q., Johnson J., Shaefer M.S., and Team C.O.D.S. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus. Pharmacotherapy 24 (2004) 307-312
59. Schrager L.K., and D'Souza M.P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280 (1998) 67-71
60. Serra C.H.D.R., Koono E.E.M., Kano E.K., Schramm S.G., Armando Y.P., and Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy brazilian volunteers: An open-label, randomized, single-dose, two-way crossover study. Clin. Ther. 30 (2008) 902-908
61. Shepp D.H., Ramirez-Ronda C., Dall L., Pollard R.B., Murphy R.L., Kessler H., Sherer R., Mertz G., Perez G., Gocke D.J., Greenberg S.B., Petersen E., Frank I., Moore M.D., McKinnis R., and Rooney J.F. A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15 (1997) 283-288
62. Stebbing J., Gazzard B., and Douek D.C. Where does HIV live?. N. Engl. J. Med. 350 (2004) 1872-1880
63. Stingl G., Rappersberger K., Tschachler E., Gartner S., Groh V., Mann D.L., Wolff K., and Popovic M. Langerhans cells in HIV-1 infection. J. Am. Acad. Dermatol. 22 (1990) 1210-1217
64. Stretcher B.N., Pesce A.J., Murray J.A., Hurtubise P.E., Vine W.H., and Frame P.T. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther. Drug Monit. 13 (1991) 325-331
65. Struble K., Murray J., Cheng B., Gegeny T., Miller V., and Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS 19 (2005) 747-756
66. Susan-Resiga D., Bentley A.T., Lynx M.D., LaClair D.D., and McKee E.E. Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart. Antimicrob. Agents Chemother. 51 (2007) 1142-1149
67. ′-triphosphate (AZTTP) levels in cultured cem T-lymphoblastoid cells. Biochem. Pharmacol. 49 (1995) 829-837
68. ′-triphosphate. Anal. Biochem. 196 (1991) 302-307
69. Tozzi, V., Zaccarelli, M., Bonfigli, S., Lorenzini, P., Liuzzi, G., Trotta, M.P., Forbici, F., Gori, C., Bertoli, A., Bellagamba, R., Narciso, P., Perno, C.F., Antinori, A., for Clinical Use of HIV Genotype Resistance Test, C.G., 2006. Drug-class-wide resistance to antiretrovirals in hiv-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther. 11, 553-560.
70. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140 (1994) 1-22
71. Tschachler E., Groh V., Popovic M., Mann D.L., Konrad K., Safai B., Eron L., diMarzo Veronese F., Wolff K., and Stingl G. Epidermal langerhans cells-a target for HTLV-III/LAV infection. J. Invest. Dermatol. 88 (1987) 233-237
72. Turner T.E., Schnell S., and Burrage K. Stochastic approaches for modelling in vivo reactions. Comput. Biol. Chem. 28 (2004) 165-178
73. Wattanagoon Y., Bangchang K.N., Hoggard P.G., Khoo S.H., Gibbons S.E., Phiboonbhanakit D., Karbwang J., and Back D.J. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers. Antimicrob. Agents Chemother. 44 (2000) 1986-1989
74. Weiss J., Rose J., Storch C.H., Ketabi-Kiyanvash N., Sauer A., Haefeli W.E., and Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 59 (2007) 238-245
75. Wilde M.I., and Langtry H.D. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 46 (1993) 515-578
76. ′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 262 (1987) 5748-5754